Qianhai Health Holdings Ltd. (HK:0911)
:0911
Want to see HK:0911 full AI Analyst Report?
Top Page
Qianhai Health Holdings Ltd.
(0911)
Select Model
Select Model
Rating:73Outperform
Price Target:
HK$0.93
▲(230.36% Upside)
Action:Upgraded
Date:05/17/26
The score is driven primarily by improved financial performance (return to profitability, stronger operating/free cash flow, and very low leverage), supported by constructive technical trends with the stock trading above key moving averages. Valuation is relatively modest on P/E, though the lack of dividend yield data tempers that component.
Positive Factors
Very low leverage / conservative balance sheet
Extremely low leverage and a large equity base materially reduce refinancing and solvency risks, providing durable financial flexibility. Over the next 2–6 months this supports stable operations, the ability to fund working capital or R&D without urgent external financing, and resilience to sector shocks.
Negative Factors
Very thin gross and net margins
Extremely low gross and net margins leave earnings highly sensitive to small cost increases or pricing pressure. This structural margin constraint limits the company's ability to build reserves, invest heavily in growth, or absorb input-cost shocks over the medium term without margin-restoring actions.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage / conservative balance sheet
Extremely low leverage and a large equity base materially reduce refinancing and solvency risks, providing durable financial flexibility. Over the next 2–6 months this supports stable operations, the ability to fund working capital or R&D without urgent external financing, and resilience to sector shocks.
Read all positive factors
Qianhai Health Holdings Ltd. (0911) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$140.64M
Dividend YieldN/A
Average Volume (3M)199.38K
Price to Earnings (P/E)7.8
Beta (1Y)-0.15
Revenue Growth30.29%
EPS Growth355.84%
CountryHK
Employees14
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.02
Shares Outstanding169,445,000
10 Day Avg. Volume241,207
30 Day Avg. Volume199,376
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.12
Price to Sales (P/S)0.07
P/FCF Ratio1.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Qianhai Health Holdings Ltd. Business Overview & Revenue Model
Company Description
Qianhai Health Holdings Limited, an investment holding company, engages in the sale of health products and electronic component products in Hong Kong. The company operates through Health-Care Products and Electronic Component Products segments. It...
Qianhai Health Holdings Ltd. Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
84
Very Positive
Cash Flow
74
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 677.12M | 519.70M | 961.29M | 1.96B | 283.40M |
| Gross Profit | 22.26M | 29.67M | -35.60M | 76.48M | 16.04M |
| EBITDA | 7.39M | 15.64M | -50.23M | -231.24M | 2.06M |
| Net Income | 5.94M | 1.31M | -52.70M | -233.70M | -888.00K |
Balance Sheet | |||||
| Total Assets | 408.39M | 407.31M | 478.12M | 534.43M | 738.63M |
| Cash, Cash Equivalents and Short-Term Investments | 61.38M | 23.51M | 19.52M | 1.64M | 2.47M |
| Total Debt | 424.00K | 1.03M | 487.00K | 1.19M | 7.83M |
| Total Liabilities | 17.19M | 21.74M | 94.00M | 97.73M | 68.09M |
| Stockholders Equity | 391.20M | 385.57M | 384.11M | 436.70M | 670.53M |
Cash Flow | |||||
| Free Cash Flow | 38.78M | 4.19M | 857.00K | -5.26M | -44.19M |
| Operating Cash Flow | 38.80M | 4.20M | 857.00K | -5.26M | -44.18M |
| Investing Cash Flow | -14.00K | 246.00K | 17.77M | 12.34M | 46.84M |
| Financing Cash Flow | -648.00K | -712.00K | -743.00K | -7.91M | -16.56M |
Qianhai Health Holdings Ltd. Technical Analysis
Positive
0.28
Price Trends
0.48
Positive
0.38
Positive
0.33
Positive
Market Momentum
0.10
Positive
56.61
Neutral
42.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0911, the sentiment is Positive. The current price of 0.28 is below the 20-day moving average (MA) of 0.79, below the 50-day MA of 0.48, and below the 200-day MA of 0.33, indicating a bullish trend. The MACD of 0.10 indicates Positive momentum. The RSI at 56.61 is Neutral, neither overbought nor oversold. The STOCH value of 42.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0911.
Qianhai Health Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$140.64M | 7.84 | 0.91% | ― | 30.29% | 355.84% | |
69 Neutral | HK$2.22B | 5.13 | 12.91% | 15.40% | -1.88% | 17.57% | |
54 Neutral | HK$211.70M | -0.15 | -30.35% | ― | -11.89% | -290.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$356.60M | 43.65 | -1.17% | 7.50% | 59.60% | -351.02% | |
45 Neutral | HK$160.48M | -4.22 | -30.35% | ― | -12.03% | 6.24% | |
42 Neutral | HK$195.65M | -3.96 | -11.18% | ― | -2.12% | -13.99% |
* Healthcare Sector Average
HK:0911
Qianhai Health Holdings Ltd.
0.83
0.63
315.00%
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.07
0.02
40.38%
HK:0455
Tianda Pharmaceuticals Ltd.
0.09
-0.05
-36.81%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.32
-0.03
-8.57%
HK:1498
PuraPharm Corp. Ltd.
0.30
-0.21
-41.18%
HK:2633
Jacobson Pharma Corporation Limited
1.17
0.05
4.46%
Qianhai Health Holdings Ltd. Corporate Events
Qianhai Health Sets June 2026 AGM to Approve Results and Board Changes
May 12, 2026
Qianhai Health Holdings Limited has called its annual general meeting for 17 June 2026 in Hong Kong, where shareholders will review and approve the audited consolidated financial statements for the year ended 31 December 2025. The meeting will als...
Qianhai Health Profit Jumps on Revenue Growth Despite Margin Pressure
Mar 18, 2026
Qianhai Health Holdings Limited, a Cayman Islands-incorporated health sector group listed in Hong Kong, reported solid top-line growth from its health-related business operations in mainland China and surrounding markets. The company continues to ...
Qianhai Health Sets March Board Meeting to Approve 2025 Results and Mull Final Dividend
Mar 4, 2026
Qianhai Health Holdings has scheduled a board meeting for 18 March 2026 to review and approve the audited financial results for the year ended 31 December 2025. The board will also consider the publication of these results and decide whether to re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.